Original Articles
Vol. 2 No. 3 (2023)
Descriptive analysis of patients positive for anti-phospholipid antibodies included in two Italian registries
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: 13 July 2023
Accepted: 20 September 2023
Accepted: 20 September 2023
985
Views
308
Downloads
Authors
The definite diagnosis of antiphospholipid syndrome (APS) depends on the laboratory performance and clinicians’ interpretation. Results from two Italian inception cohort studies of anti-phospholipid antibodies (aPL)-positive subjects, the Italian Survey on ANtiphoSpholipid antibody Positive Individuals Registry (INSPIRE) and the Survey on AnTicoagulated Patients-RegisTry (START) have been compared. Data from INSPIRE were collected by rheumatologists of the FIRMA group while those of START by physicians working in Italian thrombosis centers. Evidence on several, still unraveled, clinical and methodological aspects of ‘real life’ aPL testing and APS diagnosis was collected. In this paper, we report the characteristics of 123 cases enrolled in INSPIRE and 229 in START registries, with particular reference to the reasons why these tests were requested, the obtained aPL profile, and consequent treatment. Laboratory testing for aPL in the absence of clinical criteria defining APS was more frequent in INSPIRE (p<0.0001). The rate of patients in classification category I (more than one aPL test positive) was significantly higher in START (p<0.0001) as well as the use of warfarin. A wide variety of treatments has been observed in patients in classification category II (single aPL positivity). These data indicate that there is a need to harmonize many aspects among the various specialists dealing with APS.
Downloads
Download data is not yet available.
Citations
Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306. DOI: https://doi.org/10.1111/j.1538-7836.2006.01753.x
Cecchi I, Radin M, Rubini E, et al. Clinical manifestations in patients with antiphospholipid antibodies: Beyond thrombosis and pregnancy loss. Lupus 2021:961203321995248. DOI: https://doi.org/10.1177/0961203321995248
Rosa RF, Ugolini-Lopes MR, Zeinad-Valim AK, et al. Difficult clinical situations in the antiphospholipid syndrome. Curr Rheumatol Rep 2015;17:29. DOI: https://doi.org/10.1007/s11926-015-0502-7
Abreu MM, Danowski A, Wahl DG, et al. The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev 2015;14:401-14. DOI: https://doi.org/10.1016/j.autrev.2015.01.002
Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 2019;78:1151-9. DOI: https://doi.org/10.1136/annrheumdis-2020-218615
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725. DOI: https://doi.org/10.1002/art.1780400928
Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677-86. DOI: https://doi.org/10.1002/art.34473
Pengo V, Ruffatti A, Del Ross T, et al. Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile. J Thromb Haemost 2013;11:1527-31. DOI: https://doi.org/10.1111/jth.12264
Chayoua W, Kelchtermans H, Gris JC, et al. The (non-)sense of detecting anti-cardiolipin and anti-beta2glycoprotein I IgM antibodies in the antiphospholipid syndrome. J Thromb Haemost 2020;18:169-79. DOI: https://doi.org/10.1111/jth.14633
Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 2019;78:1296-304. DOI: https://doi.org/10.1136/annrheumdis-2019-215213
Garcia D, Akl EA, Carr R, Kearon C. Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. Blood 2013;122:817-24. DOI: https://doi.org/10.1182/blood-2013-04-496257
El Hasbani G, Viola M, Sciascia S, et al. Antiphospholipid Antibodies in Inflammatory and Autoimmune Rheumatic and Musculoskeletal Diseases Beyond Lupus: A Systematic Review of the Available Evidence. Rheumatol Ther. 2021;8:81-94. DOI: https://doi.org/10.1007/s40744-020-00273-w
How to Cite
1.
Pengo V, Sarti L, Antonucci E, Di Agostino S, Bison E, Denas G, et al. Descriptive analysis of patients positive for anti-phospholipid antibodies included in two Italian registries. Bleeding Thromb Vascul Biol [Internet]. 2023 Oct. 12 [cited 2025 Dec. 24];2(3). Available from: https://www.btvb.org/btvb/article/view/92
Copyright (c) 2023 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Similar Articles
- PO04 | Classification criteria for antiphospholipid syndrome: ACR/EULAR 2023 versus Sydney 2006 – A monocentric and retrospective study , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- CO17 | Clinical relevance of isolated anti-phosphatidylserine/ prothrombin antibody positivity , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- CO04 | Direct oral anticoagulants in antiphospholipid syndrome: a single center real-life experience , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- PO64 | A silent hemorrhage in the immuno-thrombotic chaos of antiphospholipid syndrome , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- Alice Lipari, Esmeralda Capristo, Antonietta Ferretti, Erica De Candia, Anticoagulation in obese patients: challenges and strategies , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. 3 (2025)
- Renato Marino, Silvia Linari, Marzia Leotta, Antonio Coppola, Chiara Biasoli, Maria Elisa Mancuso, Flora Peyvandi, Cristina Santoro, Ezio Zanon, Rita Carlotta Santoro, Diagnostic and management practices for inherited fibrinogen disorders: a nationwide survey of Italian Hemophilia Treatment Centers , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. 3 (2025)
- Eleonora Petito, Anna Maria Mezzasoma, Emanuela Falcinelli, Chiara Conti, Erica De Candia, Raimondo De Cristofaro, Silvia Sorrentino, Gian Marco Podda, Mariangela Scavone, Anna Falanga, Marina Marchetti, Luca Barcella, Stefania Basili, Lucia Stefanini, Andrea Boccatonda, Laura Contino, Patrizia Sciancalepore, Igor Florio, Egidio Imbalzano, Rossella Marcucci, Angela Rogolino, Patrizia Noris, Marta Panella, Rita Santoro, Maria Costanza Turi, Gaetano Vaudo, Rosa Curcio, Paolo Gresele, Persistence of functional anti-PF4 antibodies and neutrophil activation in vaccine-induced immune thrombotic thrombocytopenia , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. 3 (2025)
- PO36 | Venous stenting for symptomatic iliac thrombosis: five-years experience of single center , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- CO12 | Left internal carotid artery thrombosis in a patient with antiphospholipid antibody syndrome successfully treated with eculizumab , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- PO63 | Atypical venous thrombosis in young patient with systemic lupus erythematosus and high-risk APL profile: provoked or not? , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
1-10 of 48
Next
You may also start an advanced similarity search for this article.
Most read articles by the same author(s)
- Daniela Poli, Emilia Antonucci, Gualtiero Palareti, Roberto Facchinetti, Pietro Falco, Giuseppina Serricchio, Teresa Lerede, Lucilla Masciocco, Paolo Gresele, Sophie Testa, Major bleedings in mechanical prosthetic heart valves patients on Vitamin K antagonist treatment. Data from the PLECTRUM Study , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 2 (2022)
- Paolo Simioni, Vittorio Pengo, Paolo Prandoni, Thrombosis and hemostasis at the University of Padua: a reappraisal on the occasion of its 800th year of history , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 3 (2022)
- Daniela Poli, Walter Ageno, Emilia Antonucci, Salvatore Bradamante, Eugenio Bucherini, Paolo Chiarugi, Antonio Chistolini, Benilde Cosmi, Anna Falanga, Antonio Insana, Domenico Lione, Rosa Maria Lombardi, Giuseppe Malcangi, Rossella Marcucci, Giuliana Martini, Lucilla Masciocco, Carmelo Paparo, Daniele Pastori, Simona Pedrini, Vittorio Pengo, Pasquale Pignatelli, Andrea Toma, Sophie Testa, Gualtiero Palareti, Management of anticoagulation in atrial fibrillation patients in Italy: insight from the Atrial Fibrillation-Survey on Anticoagulated Patients Register (AF-START) , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 2 (2023)
- Cristina Legnani, Michela Cini, Sophie Testa, Alberto Tosetto, Claudia Dellanoce, Stefania Bellesso, Giuseppe Carli, Ilaria Nichele, Laura Lissandrini, Serena Zorzi, Emilia Antonucci, Gualtiero Palareti, Evaluation of Coaguchek® Pro II coagulation testing device performance to assess direct oral anticoagulant action. The DOAC-CHECK study , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 3 (2022)
- Gualtiero Palareti, Paolo Prandoni, Cristina Legnani, Emilia Antonucci, Serena Zorzi, Alberto Tosetto, Lorenza Bertù, Sophie Testa, Vittorio Pengo, Walter Ageno, Ida Martinelli, Benilde Cosmi, Eugenio Bucherini, Daniela Poli, Rationale and design of a study on D-dimer use to stratify patients after a first unprovoked venous thromboembolism for their risk of recurrence: extended low-dose Apixaban given only to patients with positive D-dimer results , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 1 (2022)
- Gualtiero Palareti, The diagnostic procedure for subjects with suspected pulmonary embolism. A recent comparison among the recommendations available from the international guidelines , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 1 (2024)
- Gianfranco De Girolamo, Luca Sarti, Sonia Cecoli, Karin Bonora, Chiara Ajolfi, Francesco Bellelli, Valeria Coluccio, Gualtiero Palareti, Marco Marietta, Safety and efficacy of treatment with vitamin K antagonists in patients managed in a network of anticoagulation services or as routine general care , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 1 (2022)
- Daniela Poli, Riccardo Tartaglia, Doris Barcellona , Paolo Bucciarelli , Antonio Ciampa, Elvira Grandone, Giuseppe Malcangi, Giuseppe Rescigno, Vincenzo Toschi, Sophie Testa, Alessandro Squizzato, Attitude to clinical research among health professionals affiliated with the Italian Federation of Centers for the Diagnosis of Thrombotic Disorders and the Surveillance of the Antithrombotic Therapies (FCSA) , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 1 (2023)
- Gualtiero Palareti, Management of atrial fibrillation: a practical and useful synopsis of last guidelines , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. 1 (2025)
- Vittorio Pengo, Comment on "Apixaban vs. aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischemic attack: subgroup analysis of the ARTESiA randomized controlled trial" , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. 2 (2025)
